ArticleScientific reports2026
Efficacy and safety of e.p.t.q. hyaluronic acid fillers in the context of aesthetic facial rejuvenation or beautification: a post-market clinical follow-up study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
This study was conducted to assess the efficacy and safety of e.p.t.q. hyaluronic acid (HA) fillers (JETEMA Co., Ltd., Yongin, Korea) in the context of aesthetic facial rejuvenation or beautification. The patients were evaluated for changes in the Wrinkle Severity Rating Scale (WSRS) scores, the Mid-Face Volume Deficit Scale (MFVDS) scores and the Medicis Lip Fullness Scale (MLFS) scores at 24 weeks from baseline and those in the investigator- and patient-assessed Global Aesthetic Improvement Scale (GAIS) scores at 24 weeks from 4 weeks and rates of adverse events (AEs), serious AEs (SAEs) and serious adverse device effects (SADEs). The WSRS, MFVDS and MLFS scores reached the highest level at 4 weeks and showed declines thereafter until 24 weeks. Moreover, there were significant changes in the WSRS, MFVDS and MLFS scores at 24 weeks from baseline (p = 0.0000 for all). The investigator- and patient-assessed GAIS scores reached the highest level at 4 weeks and showed declines thereafter until 24 weeks. Moreover, there were significant changes in the investigator- and patient-assessed GAIS scores at 24 weeks from 4 weeks (p = 0.0000 for both). There were 88 cases of AEs in 24 patients (10.39%; 95% CI 6.77-15.06), three cases of ADEs in two (0.87%; 95% CI 0.11-3.09), no cases of SAEs, SADEs and unexpected SADEs in 0 (0.00%; 95% CI 0.00-1.58) and two cases of unexpected ADEs in one (0.43%; 95% CI 0.01-2.39). In conclusion, e.p.t.q. HA fillers might be considered for aesthetic facial rejuvenation or beautification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.